Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

MLA

de Botton, Stéphane, et al. “Enasidenib vs Conventional Care in Older Patients with Late-Stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial.” Blood, vol. 141, no. 2, Jan. 2023, pp. 156–67. EBSCOhost, https://doi.org/10.1182/blood.2021014901.

APA

de Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., Ommen, H., Semochkin, S., Kim, H.-J., Larson, R. A., Koprivnikar, J., Frankfurt, O., Thol, F., Chromik, J., Byrne, J., Pigneux, A., Thomas, X., Salamero, O., Vidriales, M. B., … DiNardo, C. D. (2023). Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood, 141(2), 156–167. https://doi.org/10.1182/blood.2021014901

Chicago

de Botton, Stéphane, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, et al. 2023. “Enasidenib vs Conventional Care in Older Patients with Late-Stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial.” Blood 141 (2): 156–67. doi:10.1182/blood.2021014901.